Overview

Evaluating the Efficacy and Safety of OC-01 (Varenicline) Nasal Spray on Dry Eye Disease

Status:
Completed
Trial end date:
2021-02-17
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs and symptoms of dry eye disease (DED)
Phase:
Phase 3
Details
Lead Sponsor:
Oyster Point Pharma, Inc.
Treatments:
Varenicline